Amiwise-50 Tablet
Amisulpride 50 mg Tablets — Low-Dose Atypical Antipsychotic for Negative Symptoms
| Composition | Amisulpride 50 mg |
|---|---|
| Dosage Form | Tablet |
| Pack Type | Blister |
| Pack Size | 10 x 10 Tablets |
| MRP | ₹ 800 |
| Therapy | Neurology / Psychiatry — Atypical Antipsychotic (D2/D3 selective) |
| Storage | Store below 30 °C in a dry place, protected from light and moisture. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Amiwise-50 Tablet
Amiwise-50 Tablet contains Amisulpride 50 mg — the lower-strength variant used in the low-dose niche of Amisulpride pharmacology. At doses of 50–300 mg/day, Amisulpride preferentially blocks presynaptic D2/D3 autoreceptors, raising synaptic dopamine in the mesocortical pathway and producing a unique anti-negative-symptom effect that distinguishes it from most other antipsychotics.
Clinically, the 50 mg strength is used for predominantly negative schizophrenic symptoms (apathy, social withdrawal, blunted affect, anhedonia), for dysthymic disorder (under specialist supervision) and as a starting dose during titration. Its selectivity for dopamine receptors with little binding to other neurotransmitter systems gives it a cleaner side-effect profile than older antipsychotics.
Amiwise-50 is manufactured by Trumac Healthcare under WHO-GMP conditions and is available for monopoly-based PCD pharma franchise and third-party manufacturing — a specialty psychiatry SKU.
Indications
- Schizophrenia with predominantly negative symptoms
- Initiation of Amisulpride therapy (titration dose)
- Dysthymic disorder (specialist use)
- Adjunctive use in schizoaffective disorder
Mechanism of Action
At low doses (50–300 mg/day) Amisulpride preferentially blocks presynaptic D2/D3 autoreceptors in the mesocortical and frontal pathway, raising synaptic dopamine and ameliorating negative symptoms. Selectivity for dopamine receptors and minimal binding to serotonergic, histaminic, muscarinic or adrenergic receptors limits adverse effects.
Dosage & Administration
Predominantly negative symptoms: 50–300 mg/day in 1–2 divided doses, titrated to clinical response. Adjust in renal impairment. Prescribed by a psychiatrist.
Side Effects
Insomnia, anxiety, somnolence, weight gain, hyperprolactinaemia (galactorrhoea, amenorrhoea, sexual dysfunction). Extrapyramidal symptoms uncommon at this low dose. Dose-dependent QT prolongation — ECG monitoring at higher doses.
Contraindications & Precautions
Hypersensitivity to amisulpride. Prolactin-dependent tumours. Phaeochromocytoma. Concomitant levodopa. Severe renal impairment. Long QT syndrome. Children under 15.
Storage
Store below 30 °C in a dry place, protected from light and moisture.
Amiwise-50 Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Amiwise-50 Tablet used for?
Amiwise-50 Tablet contains Amisulpride 50 mg and is used for schizophrenia with predominantly negative symptoms (apathy, social withdrawal) and as an initial titration dose.
How does the 50 mg dose differ from 100 mg?
At low doses (50–300 mg), Amisulpride preferentially blocks autoreceptors and raises dopamine — making it effective for negative symptoms. At higher doses (>400 mg) it blocks postsynaptic receptors and treats positive symptoms.
Is Amiwise-50 available for PCD pharma franchise?
Yes, Trumac Healthcare offers Amiwise-50 Tablet on monopoly-based PCD pharma franchise and for third-party manufacturing.
How should Amiwise-50 Tablet be stored?
Store below 30 °C in a dry place, away from direct sunlight and moisture.
Is Amiwise-50 WHO-GMP certified?
Yes, Amiwise-50 Tablet is manufactured in WHO-GMP and DCGI-compliant facilities.
Related Products
- Amiwise-100 Tablet — Amisulpride 100 mg
- Amivate-10 Tablet — Amitriptyline 10 mg
- Amanzil-100 Tablet — Amantadine 100 mg